NEW YORK (GenomeWeb News) – Ignyta said on Monday it has acquired biotech firm Actagene for an undisclosed amount.

The deal, according to Ignyta, will transition it from a company focused solely on molecular diagnostics for autoimmune diseases to "an integrated Rx/Dx focus on drug and biomarker discovery and development for cancer and immunology."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.